Figure 1
The levels and kinetics of HMW adiponectin. (A) Concentrations of HMW adiponectin by sex among normal healthy subjects and recipients without GVHD, with late acute GVHD, and with National Institutes of Health cGVHD. (B) Concentrations of HMW adiponectin among normal health subjects and recipients without GVHD, with late acute GVHD, and with National Institutes of Health cGVHD according to BMI less than 18, 18 to 22, and more than 22 kg/m2 groups. (C) Concentrations of HMW adiponectin by sex and the NIH severity of cGVHD. (D) Comparison of the ratios of the later-to-prior HMW adiponectin between adjacent samples according to clinical changes in cGVHD: worsening, improving, and stable cGVHD groups. Ratio > 1 indicates that adiponectin levels increased over time; ratio = 1, adiponectin levels did not change over time; and ratio < 1, adiponectin levels decreased over time.

The levels and kinetics of HMW adiponectin. (A) Concentrations of HMW adiponectin by sex among normal healthy subjects and recipients without GVHD, with late acute GVHD, and with National Institutes of Health cGVHD. (B) Concentrations of HMW adiponectin among normal health subjects and recipients without GVHD, with late acute GVHD, and with National Institutes of Health cGVHD according to BMI less than 18, 18 to 22, and more than 22 kg/m2 groups. (C) Concentrations of HMW adiponectin by sex and the NIH severity of cGVHD. (D) Comparison of the ratios of the later-to-prior HMW adiponectin between adjacent samples according to clinical changes in cGVHD: worsening, improving, and stable cGVHD groups. Ratio > 1 indicates that adiponectin levels increased over time; ratio = 1, adiponectin levels did not change over time; and ratio < 1, adiponectin levels decreased over time.

Close Modal

or Create an Account

Close Modal
Close Modal